These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 25246428)

  • 1. Contemporary murine models in preclinical astrocytoma drug development.
    McNeill RS; Vitucci M; Wu J; Miller CR
    Neuro Oncol; 2015 Jan; 17(1):12-28. PubMed ID: 25246428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromosome number and carmustine sensitivity in human gliomas.
    Shapiro JR; Pu PY; Mohamed AN; Galicich JH; Ebrahim SA; Shapiro WR
    Cancer; 1993 Jun; 71(12):4007-21. PubMed ID: 8389658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-grade glioma mouse models and their applicability for preclinical testing.
    de Vries NA; Beijnen JH; van Tellingen O
    Cancer Treat Rev; 2009 Dec; 35(8):714-23. PubMed ID: 19767151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetically engineered mouse models of astrocytoma: GEMs in the rough?
    Reilly KM; Jacks T
    Semin Cancer Biol; 2001 Jun; 11(3):177-91. PubMed ID: 11407943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HIF‑1α/miR‑224‑3p/ATG5 axis affects cell mobility and chemosensitivity by regulating hypoxia‑induced protective autophagy in glioblastoma and astrocytoma.
    Huang S; Qi P; Zhang T; Li F; He X
    Oncol Rep; 2019 Mar; 41(3):1759-1768. PubMed ID: 30569180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
    Daher A; de Groot J
    Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling astrocytoma pathogenesis in vitro and in vivo using cortical astrocytes or neural stem cells from conditional, genetically engineered mice.
    McNeill RS; Schmid RS; Bash RE; Vitucci M; White KK; Werneke AM; Constance BH; Huff B; Miller CR
    J Vis Exp; 2014 Aug; (90):e51763. PubMed ID: 25146643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Verotoxin induces apoptosis and the complete, rapid, long-term elimination of human astrocytoma xenografts in nude mice.
    Arab S; Rutka J; Lingwood C
    Oncol Res; 1999; 11(1):33-9. PubMed ID: 10451029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational validation of personalized treatment strategy based on genetic characteristics of glioblastoma.
    Oh YT; Cho HJ; Kim J; Lee JH; Rho K; Seo YJ; Choi YS; Jung HJ; Song HS; Kong DS; Seol HJ; Lee JI; Yoon Y; Kim S; Nam DH; Joo KM
    PLoS One; 2014; 9(8):e103327. PubMed ID: 25084005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical management of high-grade astrocytoma: current and emerging therapies.
    Johnson DR; Galanis E
    Semin Oncol; 2014 Aug; 41(4):511-522. PubMed ID: 25173143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring Novel Molecular Targets for the Treatment of High-Grade Astrocytomas Using Peptide Therapeutics: An Overview.
    Guidotti G; Brambilla L; Rossi D
    Cells; 2020 Feb; 9(2):. PubMed ID: 32093304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cathepsin L silencing increases As
    Primon M; Huszthy PC; Motaln H; Talasila KM; Miletic H; Atai NA; Bjerkvig R; Lah Turnšek T
    Exp Cell Res; 2017 Jul; 356(1):64-73. PubMed ID: 28412241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular targeting of glioblastoma: Drug discovery and therapies.
    Bai RY; Staedtke V; Riggins GJ
    Trends Mol Med; 2011 Jun; 17(6):301-312. PubMed ID: 21411370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma.
    Mercurio S; Padovani L; Colin C; Carré M; Tchoghandjian A; Scavarda D; Lambert S; Baeza-Kallee N; Fernandez C; Chappé C; André N; Figarella-Branger D
    Acta Neuropathol Commun; 2013 May; 1():17. PubMed ID: 24252689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects.
    Reilly KM; Loisel DA; Bronson RT; McLaughlin ME; Jacks T
    Nat Genet; 2000 Sep; 26(1):109-13. PubMed ID: 10973261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mouse glioma gene expression profiling identifies novel human glioma-associated genes.
    Gutmann DH; Huang ZY; Hedrick NM; Ding H; Guha A; Watson MA
    Ann Neurol; 2002 Mar; 51(3):393-405. PubMed ID: 11891838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and treatment of high-grade astrocytoma.
    Sathornsumetee S; Rich JN; Reardon DA
    Neurol Clin; 2007 Nov; 25(4):1111-39, x. PubMed ID: 17964028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity of chemosensitivity in six clonal cell lines derived from a spontaneous murine astrocytoma and its relationship to genotypic and phenotypic characteristics.
    Bradford R; Koppel H; Pilkington GJ; Thomas DG; Darling JL
    J Neurooncol; 1997 Sep; 34(3):247-61. PubMed ID: 9258817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioblastoma: molecular analysis and clinical implications.
    Huse JT; Holland E; DeAngelis LM
    Annu Rev Med; 2013; 64():59-70. PubMed ID: 23043492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of treatment on long-term survivors with malignant astrocytomas.
    Imperato JP; Paleologos NA; Vick NA
    Ann Neurol; 1990 Dec; 28(6):818-22. PubMed ID: 2178330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.